SEC Form 4 · accession 0001140361-15-001625

OncoMed Pharmaceuticals Inc · OMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 9, 2015

Accepted (ET)

Jan 13, 2015 · 5:08 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001302573

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jan 9, 2015	J	712	$0.00	A	63,950	D
Common Stock^F2	holding	—	—		—	18,758	I	Directly owned by EP VIII-A
Common Stock^F2	holding	—	—		—	9,509	I	Directly owned by EP VIII-B
Common Stock^F2	holding	—	—		—	1,990,783	I	Directly owned by USVP VIII
Common Stock^F2	holding	—	—		—	19,215	I	Directly owned by AFF VIII

No Table II lines on this filing.

F1The reporting person received the shares for no consideration as part of a pro-rata distribution of shares by funds controlled by Latterell Venture Partners
F2The reported securities are owned directly by each of U.S. Venture Partners VIII, L.P. ("USVP VIII"), USVP VIII Affiliates Fund, L.P. ("AFF VIII"), USVP Entrepreneur Partners VIII-A, L.P. ("EP VIII-A") and USVP Entrepreneur Partners VIII-B, L.P. ("EP VIII-B" and together with USVP VIII, AFF VIII and EP VIII-A, the "USVP VIII Funds"). Presidio Management Group VIII, L.L.C. ("PMG VIII") is the general partner of each of USVP VIII, AFF VIII, EP VIII-A and EP VIII-B and may be deemed to have sole voting and dispositive power over the shares held by the USVP VIII Funds. PMG VIII and each of Irwin Federman, Steven M. Krausz, David Liddle, Jonathan D. Root, Casey M. Tansey and Philip M. Young, the managing members of PMG VIII who may be deemed to share voting and dispositive power over the reported securities, disclaim beneficial ownership of the reported securities held by the USVP VIII Funds except to the extent of any pecuniary interest therein.